Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Lynparza approved in the EU for prostate cancer

5 November 2020 07:10 GMT Lynparza approved in the EU for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer Only PARP inhibitor to improve overall survival vs. new hormonal agent treatments in BRCA-mutated metastatic castration-resistant prostate cancer AstraZeneca and MSD's Lynparza (olaparib) has been approved in the European Union (EU) for patients with metastatic castration-resistant prostate cancer (mCRPC) with breast cancer susceptibility gene 1/2 (BRCA1/2) mutations, a subpopulation of homologous recombination repair (HRR) gene mutations.

Forxiga approved in the EU for heart failure

5 November 2020 07:05 GMT Forxiga approved in the EU for heart failure Forxiga is the first SGLT2 inhibitor approved in the EU for heart failure with reduced ejection fraction in adult patients with and without type-2 diabetes AstraZeneca's Forxiga (dapagliflozin) has been approved in the European Union (EU) for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF) in adults with and without type-2 diabetes (T2D). Heart failure (HF) is a life-threatening chronic disease that prevents the heart from pumping sufficient levels of blood around

AZN: Year-to-date and Q3 2020 results

AstraZeneca PLC 5 November 2020 07:00 GMT Year-to-date and Q3 2020 results On track to meet full-year guidance; executing the strategy of sustainable growth through innovation In the year to date, AstraZeneca delivered increases in the top line, profit and cash, underpinned by a strategy of sustainable growth through innovation. Total Revenue was in line with expectations and the operating performance continued to improve, with earnings growth in the third quarter reflecting Collaboration Revenue and Other Operating Income and Expense weighted towards the fourth quarter. As a

Interim report January-September 2020

· Profit from property management attributable to parent company shareholders amounted to SEK 3,146m (2,970), corresponding to an increase per share by 6 % to SEK 17.48 (16.50) · Long term net asset value amounted to SEK 362.77 per share (311.10) · Rental income amounted to SEK 6,079m (5,577) · Profit after tax attributable to parent company shareholders amounted to SEK 3,063m (4,473) corresponding to SEK 17.02 per share (24.85) Profit from property management for the period amounted to SEK 3,682m (3,398). Profit from property management attributable to parent company

Q2 Report – 30 September 2020

Flexion continues its strong growth with total revenue up by 168% and gross profit up by 190% resulting in positive adjusted EBITDA[‡ ]on IAP revenue for the first time.July 2020 to September 2020 performance · Total revenue increased by 168% to GBP 6.2m (GBP 2.3m)* · Gross profit increased by 190% to GBP 0.8m (GBP 0.3m) · Adjusted EBITDA[‡] improved by 125% to GBP 0.1m (GBP -0.5m) · Operating result improved by 110% to an operating profit of GBP 0.05m (GBP -0.5m) · Earnings per share amounted to GBP 0.08 pence (GBP -1.14 pence) · Cash amounted to GBP 3.7m (GBP 3.1m)

Biotage AB (publ) Interim report January-September 2020

Strong operating margin with good cost control July - September · Net sales amounted to 262.6 MSEK (282.7), a decrease by 7.1 percent and organically* a decrease by 2.7 percent. · Operating profit amounted to 60.7 MSEK (64.3). · Operating margin amounted to 23.1 percent (22.8). · Result after tax amounted to 37.4 MSEK (66.6). · Earnings per share was 0.57 SEK (1.02) before and after dilution. · The cash flow from operating activities decreased to 73.7 MSEK (79.9). · Net cash* at September 30 amounted to 90.2 MSEK (net debt -69.2). · Cash and cash equivalents

Karnov Group reports third quarter results 2020

Stable quarter, strong resultFINANCIAL HIGHLIGHTS THIRD QUARTER · Net sales up 2% to SEK 193 m (190), organic growth was 3%. · EBITA amounted to SEK 77 m (69) with EBITA margin of 39.9% (36.5%). · Adjusted EBITA increased by 4% to SEK 77 m (74) and adjusted EBITA margin was 39.9% (38.9%). · Net result amounted to SEK 28 m (32). · Earnings per share after dilution amounted to SEK 0.28 (0.33). · Adjusted operating cash flow amounted to SEK -1 m (2). CEO flemming breinholt comments on the quarter: With a steady growth in our online offering and continued focus on

Interim Report January–September 2020

Active in the development of SlakthusområdetIn July, John Mattson took possession of three leasehold properties in Slakthusområdet in the City of Stockholm, which we acquired in May. The leaseholds are in a prime location near the future Metro station entrance in the area, where we plan to drive a detailed development plan for starting the development of new housing and workplaces in 2023. Base and total upgrades for apartments built in the 1950s and 1960s on Lidingö are continuing according to the scope planned and John Mattson is nearing its goal to totally upgrade at least 130

BONESUPPORT HOLDING AB (publ) – Publishes Q3 2020 Interim report

Lund, Sweden, 08:00 am CET, November 5, 2020 – BONESUPPORT HOLDING AB (publ), an emerging leader in orthobiologics for the management of bone injuries, today publishes the interim report for the third quarter 2020. STRONG GROWTH IN NORTH AMERICA. GRADUAL RECOVERY IN EUROW JULY - SEPTEMBER 2020 · Net sales increased by 23 percent and amounted to SEK 48.1 million (39.1). · The North America (NA) segment reported a sales increase of 53 percent. · The Europe & Rest of the World (EUROW) segment reported a 4 percent decline in sales. · The gross margin improved to 91.4 percent

Interim report January-September 2020

A QUARTER THAT KICKED OFF A NEW BUSINESS PLANJuly - September 2020 ·Order bookings amounted to SEK 961 million (1,792) · Income amounted to SEK 1,498 million (1,376) · The operating loss amounted to SEK 79 million (5), of which non-recurring items amounted to a negative SEK 65 million · Cash flow from operating activities amounted to an outflow of SEK 167 million (164) ·  Cash flow for the period amounted to SEK 7 million (0) · The loss for the period amounted to SEK 66 million (27) · New long-term financial targets have been adopted in the new business plan

Eltel Group: Interim report January–September 2020

July–September 2020 · Net sales EUR 226.7 million (281.8). Total growth -19.6% and organic growth[1)] in Power and Communication -12.3% · Operative EBITA[2)] EUR 6.7 million (4.1) and operative EBITA margin 2.9% (1.5) · Items affecting comparability EUR -0.7 million (0.2) include asset held for sale · Operating result (EBIT) EUR 5.8 million (3.9) and EBIT margin 2.6% (1.4) · Net result EUR 3.1 million (-3.9) · Earnings per share EUR 0.02 (-0.03), basic and diluted · Cash flow from operating activities EUR -16.2 million (6.7) January–September 2020 · Net sales

Swedbank Economic Outlook: Autumn darkness surrounds the recovery – but there is scope for growth

The outlook for economic recovery has worsened during the autumn. The increasing spread of the coronavirus is causing a slowdown in the economy. The recovery has been uneven, and many sectors continue to struggle. However, Sweden’s public finances remain strong, which means that continued expansionary fiscal policy and structural reforms are possible, according to the latest Swedbank Economic Outlook.The COVID-19 pandemic continues to determine the course of economic development. Despite a strong recovery during the summer, global GDP is expected to decline by 4 per cent this year. Against

Polygiene AB (publ.) Interim Report July 1–September 30, 2020

Strongest quarter ever, new strong partnership agreements in placeQ3 in brief · The best quarter ever with a net sales of 22.9 (20.5) and with a positive growth by 11.7 % compared to the same period last year. · The operating profit/loss before tax for the period has improved over the previous year and amounted to MSEK 2.4 (2.0). · The gross margin has increased at 70.4 (69.9) %. · The cash flow in the third quarter was positive, MSEK 0.5 (1.8). Events during Q3 2020 (July-September) · Polygiene is overall winner in Scandinavian Outdoor Group (SOG) awards 2020! Each

LeoVegas AB Q3: Quarterly report 1 July– 30 September 2020

“Record-large customer base and strong start to Q4”– Gustaf Hagman, Group CEO THIRD QUARTER 2020: 1 julY–30 september · Revenue increased by 1% to EUR 88.9 m (88.2). Organic growth in local currencies was 2%. · EBITDA was EUR 11.9 m (12.7), corresponding to an EBITDA margin of 13.4% (14.4%). · The number of depositing customers was 438,691 (347,464), an increase of 26%. · Earnings per share were EUR 0.04 (0.05) before and after dilution, while adjusted earnings per share were EUR 0.08 (0.09). Events during the quarter · GoGoCasino and Livecasino.com launched in

Quarterly Report Q3-2020: Raised market estimate for Mangoral and preparing for market launch

Ascelia Pharma AB (publ) (ticker: ACE) today published its quarterly financial report for Q3-2020 (July – September 2020), which is now available on the company’s website: https://www.ascelia.com/ir-media/reports-presentations/SIGNIFICANT EVENTS IN Q3-2020 · First commercial scale manufacturing of Mangoral · Proceeds from directed share issue received in the beginning of July SIGNIFICANT EVENTS AFTER THE PERIOD · In October, the estimate of the addressable market for Mangoral was upgraded to $500-600 million annually (previously $350-500 million) · In November,

Interim report for Q3 2020

Weak quarter but the need for infection prevention greater than everThird quarter (July-September 2020) · Revenues amounted to SEK 34,1 (67,2) million a decreased by 49% (adjusted for currency -46%) due to Covid-19 effects on both license and BIP revenues. In addition, no new license revenue was generated within the quarter while the third quarter previous year included SEK 29,4 million in new license revenue from Zimmer Biomet. · EBITDA amounted to SEK -3,1 (36,5) million with an EBITDA-margin of -9% (54%). · Operating profit amounted to SEK -14,3 (25,9) million. · Net profit/

Interim report January - September 2020

Recovery for Accessibility in the third quarter with organic revenue growth of 6.2%, while the two smaller business units remained negatively affected by Covid-19. A more competitive cost base, mainly driven by the Lift Up Program, led to improved profit year-on-year despite the continuing pandemic.Third quarter 2020 · Revenue amounted to MEUR 53.2 (59.7). · Organic growth was -1.2%. · The gross margin was 42.2% (40.3). · Adjusted EBITA amounted to MEUR 6.1 (3.9), corresponding to a margin of 11.5% (6.5). · EBIT was MEUR 4.4 (2.3). · Net profit (including discontinued

Interim report Q3, 2020

Third quarter 2020 · Net sales amounted to MSEK 4.3 (2.5) · EBITDA amounted to MSEK -1.6 (-5.6) · EBT amounted to MSEK -10.1 (-10.7) · Earnings per share before dilutions amounted to SEK  -0.05 (-0.08) · SpectrumOne’s rights issue of free-of-payment units is oversubscribed · SpectrumOne acquires the digital marketing agency The Trigger Company AB · SpectrumOne has closed acquisition of Å-Data Infosystems AB Significant events after the reporting period · Extraordinary General Meeting elected Anders Hugosson as a new member of the Board and gave mandate to the

Accelerated implementation of growth strategy

Acroud AB (publ) has had another quarter characterized by intensive change management where a more offensive growth strategy has been implemented. The strategy entails an increased focus on acquisitions and partnerships to increase the growth rate and enable Acroud to become a major challenger in Sports Betting and in markets such as the US.THIRD QUARTER 2020   · Revenue amounted to EUR 2,376 (3,467) thousand. · EBITDA amounted to EUR 961 (1,867) thousand. · Profit after tax was EUR 327 (1,141) thousand. Adjusted profit after tax (before currency effects) was EUR 162 (816)

Metso Outotec launches Filter Optimizer for improved filter performance and optimized energy consumption

Metso Outotec Corporation’s press release on November 5, 2020, at 09:00 a.m. EETMetso Outotec is introducing the innovative Filter Optimizer to further boost the performance of its Larox® PF filter in the mining and chemical industry processes. The game-changing Filter Optimizer improves the PF filter performance by enabling more precise control over the solid/liquid separation process. The new optimizer stabilizes the effect of upstream process variations, provides tools for improved process control and reduces the need for manual intervention. In mining processes, the new Filter

INTERIM REPORT THIRD QUARTER 2020

CONTINUED STRONG PERFORMANCE AND KEY CUSTOMER WINSTHIRD QUARTER · Revenues increased by 20.7% to €40.1 million (33.2). · EBITDA increased by 25.7% to €6.6 million (5.2). · The EBITDA margin amounted to 16.4% (15.7%). · EBIT increased by 15.5% to €4.9 million (4.3). · Earnings after tax amounted to €3.8 million (4.4). · Earnings per share, basic and diluted, amounted to €0.08 (0.09). · First time depositors (FTDs) increased by 10.1% to 132.0 thousand (119.9).  NINE MONTHS ·Revenues increased by 18.5% to €117.5 million (99.2). · EBITDA increased by 8.5%

Loomis publishes the interim report for January – September 2020 and removes the revenue target for 2021

Third quarter 2020Revenue for the third quarter amounted to SEK 4,709 million (5,492). Real growth was -7 percent (6) and organic growth was -9 percent (3). Loomis operating income (EBITA)[1)] amounted to SEK 517 million (737) and the operating margin was 11.0 percent (13.4). Excluding Loomis Pay, the operating margin was 11.5 percent (13.4). Income before taxes amounted to SEK 361 million (660) and income after taxes was SEK 246 million (492). Earnings per share before and after dilution amounted to SEK 3.27 (6.54). Cash flow from operating activities[2)] amounted to SEK 587

Bactiguard maintains clear growth strategy and updates financial targets

Bactiguard presents updated financial targets for 2025 in connection with the company's financial report for the third quarter of 2020.Bactiguard's growth strategy for the coming five-year period up to 2025 is based on a continued roll-out of Bactiguard's technology, with a focus on new license agreements and a broader product portfolio. “We are confident in the strength of Bactiguard's technology for various types of medical applications, both for short-term and long-term use. We have several interesting licensing projects ongoing and see new, exciting business opportunities. The

Implementation of share split in Sweco AB (publ)

As previously communicated, the Extraordinary General Meeting of Sweco AB (publ) (“Sweco”) on October 22, 2020, resolved in favour of a split of the company’s shares whereby each existing share of the company is divided into three shares of the same class (ratio 3:1). The following applies for the share split: · The last day of trading before the share split is November 9, 2020. · The first day of trading after the share split is November 10, 2020. · Pursuant to the authorisation granted by the Extraordinary General Meeting, the Board of Directors has resolved that the record

Read original
There are no items matching the current filter
There are no more items matching the current filter
Back to top